Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 10;14:61. doi: 10.1186/s13073-022-01066-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Neutralisation titres against the B.1, B.1.617.2 and BA.1 SARS-CoV-2 variants in naïve and previously infected subjects according to vaccination. a Neutralising antibody titres against B.1, B.1.617.2 and BA.1 SARS-CoV-2 variants in (left) previously infected (Friedman test followed by Dunn’s multiple comparisons test, serum of previously infected subjects with one vaccine dose against B.1 versus B.1.617.2 and BA.1, P = 0.004 and P < 0.0001 respectively; serum of previously infected subjects with two vaccine doses against B.1 versus B.1.617.2 and BA.1, P = 0.02 and P < 0.0001, respectively) and (right) naïve subjects (Friedman test followed by Dunn’s multiple comparisons test, serum of naïve subjects with two doses of vaccine against B.1 versus B.1.617.2 and BA.1, P = 0.03 and P <0.0001, respectively). Asterisks indicate *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. b, c Fold changes in serum neutralisation titres of previously infected subjects with b one dose of vaccine and c two doses of vaccine tested for B.1.617.2 and BA.1 variants compared to B.1 (fold change of 4× and 16× for both one or two doses of vaccine for B.1.617.2 and BA.1, respectively). Previous infection is defined according to the ground truth definition given in the text